Improve Medical(SZ:300030)2025-01-17 14:10Financial Performance - The company expects a net loss of between RMB 110 million and RMB 150 million for the fiscal year 2024, compared to a net loss of RMB 63.20 million in the same period last year, representing a year-on-year change of -137.33% to -74.04%[3] - The expected operating revenue for the period is approximately RMB 590 million, reflecting a year-on-year decline of about 8.9%[5] - The expected net loss after deducting non-recurring gains and losses is projected to be between RMB 65 million and RMB 90 million, compared to a loss of RMB 74.52 million in the previous year[3] Investment and Income - The company anticipates a decrease in investment income, primarily due to the fair value changes of its investment in Shenzhen Yanghe Biomedical Industry Investment Co., which is expected to impact profits negatively[6] - Non-recurring gains and losses are expected to negatively impact the net profit attributable to shareholders by between RMB -60 million and RMB -45 million, compared to a positive impact of RMB 11.32 million in the previous year[6] Expense Management - The company has implemented measures to control expenses and optimize the expense structure, leading to a projected decrease in period expenses and expense ratio[6] Asset Review and Impairment - The company plans to conduct a comprehensive review and preliminary testing of assets for potential impairment, which may lead to impairment losses on goodwill, inventory, and fixed assets[6] Financial Data and Investor Advisory - The financial data presented is preliminary and has not been audited by the accounting firm, with no significant disagreements reported between the company and the auditors[4] - The company advises investors to make cautious decisions based on the preliminary nature of the financial data and to be aware of investment risks[7] - The company will provide more detailed financial data in its annual report, which will supersede the preliminary estimates[7]